Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Dec 20, 2021
Date Accepted: Jun 16, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Assessing the Valuation and Longevity of the Telehealth Sector as the United States Moves Towards a Post-COVID-19 Reality
ABSTRACT
The telehealth sector of healthcare delivery experienced exponential growth at the start of the pandemic, and virtual care quickly became essential for the ongoing safety of patients and providers. When vaccines were introduced, telehealth companies lost value as the necessity of virtual care appeared to end. Presently, both incumbents and new entrants to the space are seeking ways to innovate, gain investor and customer buy-in, and overcome competitors. New companies are hoping to be seen not as a pandemic-era substitute, but instead a beneficial option utilized for having cutting edge technology, convenience, and overall health benefits. This struggle is reflected in fluctuating stock prices and dropping valuations. While investors may be reasonably hesitant regarding individual telehealth companies, the industry can expect slowed but continued growth – with the potential for another explosion as subsequent global pandemics loom on the horizon.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.